For instance, a CRISPR/Cas9-mediated mutagenesis screen identified variants of the MAPK pathway genes, MEK1 and BRAF1, that are resistant to the inhibitors selumetinib and vemurafenib, respectively, in melanoma cell lines (Donovan et al., 2017). The gene discussed is BRAF; the disease is melanoma.